Northwestern Mutual Wealth Management Co. Sells 4,250 Shares of Transdigm Group Incorporated $TDG - MarketBeat
π Northwestern Mutual Wealth Management reduced its TDG stake by 61.8%, selling 4,250 shares in Q4.
π Transdigm Group reported Q1 EPS of $9.85, surpassing the consensus estimate of $9.46.
π° Revenue surged to $2.54 billion, marking an 18.3% increase compared to the previous year.
π The company raised its FY2026 EPS guidance range to $38.83-$40.21.
π€΅ Insider selling was prominent, with Director W. Nicholas Howley and COO Joel Reiss executing multi-million dollar sales.
π Susquehanna lowered its price target from $1,400 to $1,350 and issued a 'Neutral' rating.
βοΈ Weiss Ratings downgraded the stock from 'Buy' to 'Hold' in early April.
πΌ Morgan Stanley increased its price target to $1,680 and maintained an 'Overweight' rating.
π΅ The current consensus average price target stands at $1,524.18 with a 'Moderate Buy' rating.
π Institutional ownership remains high at 95.78% of the company's total shares.
- Transdigm Group delivered strong quarterly results with EPS of $9.85, significantly topping analyst expectations of $9.46.
- Revenue growth was robust, increasing by 18.3% year-over-year to reach $2.54 billion.
- The company demonstrated confidence in its future trajectory by raising its FY2026 EPS guidance to between $38.83 and $40.21.
- Morgan Stanley upgraded the stock with an 'Overweight' rating and raised its price target to $1,680.
- The company maintains a high institutional ownership level of 95.78%, indicating strong confidence from major investors.
- Northwestern Mutual Wealth Management significantly reduced its position by 61.8% in the fourth quarter.
- Recent insider selling activity is notable, with Director W. Nicholas Howley and COO Joel Reiss collectively selling over $15 million in shares.
- Susquehanna Financial Group downgraded the stock to 'Neutral' and cut its price target from $1,400 to $1,350.
- Weiss Ratings downgraded Transdigm Group from a 'Buy' rating to a 'Hold' rating.
- BNP Paribas Exane lowered its price objective from $1,800 to $1,750 despite maintaining an 'Outperform' rating.